Главная
Study mode:
on
1
Intro
2
Disclosures
3
Risk Factors - Genetic
4
Risk Factors - Environmental
5
Modifiable Risk Factors - Smoking
6
Modifiable Risk Factors - Gut Microbiome
7
2017 McDonald Diagnostic Criteria - RRMS
8
Earlier Diagnosis = Earlier Treatment
9
Earlier Treatment = Better Outcomes
10
Goals of Therapy/Monitoring - NEDA
11
Neurofilament light chain (NFL)
12
Diagnostic Challenges
13
Diagnostic Accuracy - MOG antibody
14
Natural Hx - Inflammation to Degeneration
15
15 FDA Approved Treatments for RRMS
16
Better Therapies = Better Outcomes
17
1 FDA Approved Treatment for PPMS
18
Progressive MS Research
19
Therapies Support Mitochondria
20
Stem Cell Therapy
Description:
Explore the current state of Multiple Sclerosis (MS) diagnosis and treatment in this comprehensive 1-hour 25-minute lecture by Dr. Lucas B. Kipp from Stanford University. Delve into risk factors, including genetic and environmental influences, with a focus on modifiable factors like smoking and gut microbiome. Learn about the 2017 McDonald Diagnostic Criteria for Relapsing-Remitting MS and the importance of early diagnosis and treatment for better outcomes. Discover the goals of therapy, including the concept of No Evidence of Disease Activity (NEDA), and the use of neurofilament light chain as a biomarker. Examine diagnostic challenges, including MOG antibody testing, and the natural history of MS progression from inflammation to degeneration. Explore the 15 FDA-approved treatments for Relapsing-Remitting MS and the single approved treatment for Primary Progressive MS. Gain insights into ongoing research in progressive MS, therapies supporting mitochondrial function, and the potential of stem cell therapy in MS treatment. Read more

Multiple Sclerosis - The State of the Art

Stanford University
Add to list
0:00 / 0:00